Health
AbbVie Lifts Profit Guidance as Newer Drugs Drive Sales Beat
An AbbVie Inc. pharmaceutical manufacturing facility in Sligo, Ireland.
Photographer: Rob Stothard/BloombergThis article is for subscribers only.
AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in trade policy.
The drugmaker raised its 2025 adjusted earnings by 10 cents to a range of $12.09 to $12.29 a share. That “does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie’s business,” according to a statement.